IMT504 Provides Analgesia by Modulating Cell Infiltrate and Inflammatory Milieu in a Chronic Pain Model

LEIGUARDA, CANDELARIA; TATE, PABLO; BISAGNO, VERÓNICA; POTILINSKI, MARÍA CONSTANZA; VILLAR, MARCELO J.; CONSTANDIL, LUIS; RUBIONE, JULIA; MONTANER, ALEJANDRO; BRUMOVSKY, PABLO R.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY

SPRINGER

Año: 2020

1557-1890

IMT504 is a non-CPG, non-coding synthetic oligodeoxinucleotide (ODN) with immunomodulatory properties and a novelinhibitory role in pain transmission, exerting long-lasting analgesic effects upon multiple systemic administrations. However,its mechanisms of anti-nociceptive action are still poorly understood. In the present study in male adult rats undergoing complete Freund?s adjuvant-induced hindpaw inflammation, we focused in the analysis of the immunomodulatory role of IMT504 over the cellular infiltrate, the impact on the inflammatory milieu, and the correlation with its anti-allodynic role. By means of behavioral analysis, we determined that a single subcutaneous administration of 6 mg/kg of IMT504 is sufficient to exert a 6-week-long full reversal of mechanical and cold allodynia, compromising neither acute pain perception nor locomotor activity. Importantly, we found that the anti-nociceptive effects of systemic IMT504, plus quick reductions in hindpaw edema, were associated with a modulatory action upon cellular infiltrate of B-cells, macrophages and CD8+ T-cells populations. Accordingly, we observed a profound downregulation of several inflammatory leukocyte adhesion proteins, chemokines and cytokines, as well as of β-endorphin and an increase in the anti-inflammatory cytokine, interleukin-10. Altogether, we demonstrate that at least part of the anti-nociceptive actions of IMT504 relate to the modulation of the peripheral immune system at the site of injury, favoring a switch from pro- to anti-inflammatory conditions, and provide further support to its use against chronic inflammatory pain.